5PSQ-093 Persistence of treatment with interleukin -17 inhibitors in skin disorders

Abstract

<h3>Background and importance</h3> Ixekizumab and secukinumab are two monoclonal antibodies indicated in psoriasis (Ps), psoriatic arthritis (PsA) and ankylosing spondylitis in patients with inadequate response to conventional treatments by selective neutralisation of interleukin-17 (IL-17). <h3>Aim and objectives</h3> Evaluating the persistence of IL-17 inhibitors in patients diagnosed with psoriasis and psoriatic arthritis in a reference hospital of the area. <h3>Material and methods</h3> We made a retrospective study (May 2017 to August 2021) in which we included all patients who initiated treatment with IL-17 inhibitors. Data of sex, age, diagnostic, previous biological treatment, start date and last dispensation date were collected. Il-17’s persistence was calculated in months using the Kaplan–Meier method and log-rank test to compare the survival along diagnostic, drug and line of treatment using SPSS Statistics, considering a p value &lt;0.05. <h3>Results</h3> A total of 80 patients were included (33 with ixekizumab (60% Ps, 40% PsA) and 47 with secukinumab (49% Ps, 51% PsA). 36% were men, median age 54 (IQR 42–60) years. 31.25% were treated as first line, 13.75% as second line and 55% at third line or more with a median of two previous biological drugs. 46.25% discontinued treatment during the study (60% ixekizumab, 50% secukinumab). 55% of patients had been treated for more than a year with IL-17 (35% of them for more than 2 years) and the rest 45% interrupted treatment before completing a year (58% for less than 6 months). IL-17’s persistence was 24.1 months (95% CI 17.9 to 30.2) vs 30.9 months (95% CI 24.3 to 37.4) for ixekizumab and secukinumab, respectively, and did not show a significant difference (p=0.774). Comparing between groups, there were no differences in ixekizumab’s persistence in Ps vs PsA (24.5 vs 14.2 months, p=0.97), secukinumab’s persistence in Ps vs PsA (32.5 vs 24.3 months, p=0.6), Ps’ persistence of ixekizumab vs secukinumab (p= 0.79) and PsA’s persistence of ixekizumab vs secukinumab (p=0.83). Regarding the persistence of the treatment line this was similar in each group, and did not show any statistical differences. <h3>Conclusion and relevance</h3> Both IL-17 inhibitors show a similar and considerable persistence of nearby 30 months globally. No significant differences were found either between between the drugs, diagnostics nor line of treatment. <h3>References and/or acknowledgements</h3> 1. Egeberg A. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. <i>J Am Acad Dermatol</i> 2019;<b>81</b>(1):173–178. <h3>Conflict of interest</h3> No conflict of interest